The size of the High Throughput Screening Market in the Middle East and Africa is anticipated to grow at 6.9% CAGR from 2020 to 2025, and it is estimated that the Middle East and Africa market was valued at USD 1.3 billion in 2020 and is expected to reach USD 1.82 billion by 2025.
The rise in the number of potential drug targets, advancements of technologies leading to the emergence of innovative technologies and platforms like analytical tools that deal with massive amounts of data drive market growth. Growth in demand for high throughput screening devices in stem cell research for assessing excretion, metabolism, distribution, and absorption characteristics and investigation of functional activity are significant drivers of the MEA high throughput screening market.
Also, the availability of government funding, collaborations of research, and academic institutions with pharmaceutical industries for developing innovative ways for drug delivery are further catalyzing the growth of the MEA high throughput screening market.
The factors that provide growth opportunities for expansion of high throughput screening market during the forecast period are the evolution of preclinical drug development and discovery systems through the adoption of human stem cell-based high throughput screenings and assays. Emerging economies of countries are increasing the market's growth opportunities due to rapid growth in pharmaceutical industries and the integration of innovative technologies, a significant push for research by governments of these countries in the life sciences industry.
Restraints that are challenging the growth of high throughput screening market are costs, the requirement of extensive automation techniques, capital intensive nature, and budget restrictions for academic research purposes. There is an increased requirement for instruments in biotechnological and pharmacy companies, resulting in a notable rise in these companies' capital costs that are expected to limit the MEA high throughput screening market during the forecast period.
This research report has been segmented and sub-segmented into the following categories:
By End User:
Regionally, South Africa and Saudi Arabia are witnessed to grow with the highest CAGR in the MEA high throughput screening market during the forecast period. Technological advancements in high throughput growing pharmaceutical research and development expenses are likely to fuel the market growth during the historical period. The availability of funds from the government integrated with developing common diseases is propelling the market.
The other countries like UAE, Ethiopia, Israel, Sudan, Kenya, Egypt, and rest of the MEA are expected to have decent growth in the region's market.
The leading companies leading in the MEA High Throughput Screening Market profiled in the report are Agilent Technologies Inc., Danaher Corporation, Thermo Fisher Scientific Inc., PerkinElmer Inc., Tecan Group Ltd., Millipore, Bio-Rad Laboratories, Hamilton Company, Axxam S.p.A., and Aurora Biomed.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Consumables and Reagents
5.1.4 Software and Services
5.1.5 Y-o-Y Growth Analysis, By Product
5.1.6 Market Attractiveness Analysis, By Product
5.1.7 Market Share Analysis, By Product
5.2.2 Cell-based Assays
220.127.116.11 2D Cell Culture
18.104.22.168 3D Cell Culture
22.214.171.124.1 Scaffold-Based Technology
126.96.36.199.1.2 Inert Matrix/Solid Scaffolds
188.8.131.52.2 Scaffold-Free Technology
184.108.40.206.2.2 Hanging-Drop Plates
220.127.116.11.2.3 Ultra-Low Binding Plates
18.104.22.168.2.4 Other Scaffold-Free Technologies
22.214.171.124 Perfusion Cell Culture
5.2.4 Ultra-High-Throughput Screening
5.2.5 Label-Free Technology
5.2.7 Y-o-Y Growth Analysis, By Technology
5.2.8 Market Attractiveness Analysis, By Technology
5.2.9 Market Share Analysis, By Technology
5.3.2 Target Identification
5.3.3 Primary Screening
5.3.6 Y-o-Y Growth Analysis, By Application
5.3.7 Market Attractiveness Analysis, By Application
5.3.8 Market Share Analysis, By Application
5.4 End User
5.4.2 Pharmaceutical And Biotechnology Companies
5.4.3 Academic And Government Research Institutes
5.4.4 Contract Research Organizations
5.4.6 Y-o-Y Growth Analysis, By End User
5.4.7 Market Attractiveness Analysis, By End User
5.4.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Product
184.108.40.206 By Technology
220.127.116.11 By Application
18.104.22.168 By End User
6.1.4 Market Attractiveness Analysis
22.214.171.124 By Geographical Area
126.96.36.199 By Product
188.8.131.52 By Technology
184.108.40.206 By Application
220.127.116.11 By End User
6.1.5 Market Share Analysis
18.104.22.168 By Geographical Area
22.214.171.124 By Product
126.96.36.199 By Technology
188.8.131.52 By Application
184.108.40.206 By End User
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Agilent Technologies Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Danaher Corporation
8.3 Thermo Fisher Scientific Inc.
8.4 PerkinElmer Inc.
8.5 Tecan Group Ltd.
8.7 Bio-Rad laboratories
8.8 Hamilton Company
8.9 Axxam S.p.A.
8.10 Aurora Biomed.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures